Original Research
Effect of Triple Therapy with Budesonide-Formoterol-Tiotropium Versus Placebo-Tiotropium on Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease

Samuel L Krachman, DO1 Maria Elena Vega, MD1 Daohai Yu, PhD2 Joseph Demidovich, DO1 Harsh Patel, MD1 Frederic Jaffe, DO1 Xavi Solar, MD3 Tasheen Shariff, RPSGT1 Gilbert E D'Alonzo, DO1 Wissam Chatila, MD1 Sheila Weaver, DO1 Yasmin Daraz1* Sydney Cohen1* Gerard J Criner, MD1

1Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia Pennsylvania, United States

2Department of Clinical Sciences, Temple Clinical Research Institute, Lewis Katz School of Medicine, Temple University, United States

3Department of Pulmonary, Critical Care, and Sleep Medicine University of California, San Diego, California, United States

*student


Corresponding Author:
Samuel L. Krachman, DO
Lewis Katz School of Medicine at Temple University
3401 North Broad St.
Philadelphia, Pa. 19140
Office: (215) 707-4678 Fax: (215) 707-6867
E-Mail: samuel.krachman@tuhs.temple.edu

Running Head: Effect of Triple therapy of Budesonide-Formoterol and Tiotropium on Sleep Quality
Abbreviations: chronic obstructive pulmonary disease, COPD; rapid eye movement, REM; quality of life, QOL; obstructive sleep apnea, OSA; apnea-hypopnea index, AHI; Epworth sleepiness scale, ESS; Pittsburgh sleep quality index, PSQI; COPD specific St George’s respiratory questionnaire, SGRQ-C; Short form 36, SF 36.

Key Words: Emphysema, COPD, sleep quality, nocturnal oxygen desaturation.

Funding: The study was supported by a grant from AstraZeneca. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Abstract

**Background:** Factors responsible for poor sleep quality in patients with chronic obstructive pulmonary disease (COPD) includes the effects of medications. The study evaluates the effect of the inhaled triple therapy with budesonide-formoterol-tiotropium versus placebo-tiotropium on sleep quality in COPD patients.

**Methods:** Twenty-three patients (11 (48%) males; age 55 (51-60, 48-75) yrs; body mass index [BMI] 25 (22-30, 18-40) kg/m²; FEV₁ 1.10 (0.80-1.90, 0.60-2.80) L, 42 (31-62, 24-75) % predicted were studied. Ten patients were randomized to budesonide-formoterol-tiotropium and 13 patients to placebo-tiotropium. At baseline and after 28 days patients completed spirometry, polysomnography, an Epworth sleepiness scale (ESS), Pittsburgh sleep quality index (PSQI), COPD-specific St. George’s Respiratory Questionnaire (SGRQ-C) and short form 36 (SF 36).

**Results:** After 28 days there was a significant 29% increase in the bedtime FEV₁ in the budesonide-formoterol-tiotropium group (from 0.75 (0.55-1.30, 0.50-2.40) L to 1.00 (0.75-1.55, 0.50-3.00) L p=0.031), with no change in the placebo-tiotropium group (from 1.20 (0.80-1.50, 0.60-1.90) L to 1.15 (0.75-1.55, 0.50-1.80) L, p=0.91). No change was found post treatment in sleep efficiency or total sleep time in both the budesonide-formoterol-tiotropium group (from 78 (72-92, 62-98)% to 88 (77-92, 40-98)%, p=0.70 and 290 (268-358, 252-382) min to 342 (303-358, 157-372) min, p=0.77, respectively) and the placebo-tiotropium group (from 82 (75-88, 46-93)% to 84 (77-87, 62-94)%, p=0.96 and 320 (292-350, 180-378) min to 339 (303-349, 241-366) min, p=0.79, respectively). While there was no change in the arousal index in the budesonide-formoterol-tiotropium group (9 (5-16, 0-48) arousals/hr to 14 (9-17, 2-36)
arousals/hr, p=0.43), a significant increase was seen in the placebo-tiotropium group (11 (4-13, 3-32) arousals/hr to 17 (11-21, 2-33) arousals/hr, p=0.027). Similarly, there was no change in the ESS in the budesonide-formoterol-tiotropium group (6 (3-8, 0-11) to 6 (5-8, 0-11), p=0.44), but a marginally significant increase in the placebo-tiotropium group (8 (5-12, 2-18) to 10 (7-13, 5-18), p=0.07), with a significant difference in the ESS 28 days post treatment between the 2 groups (6 (5-8, 0-11) vs. 10 (7-13, 5-18), p=0.043).

There was no significant change in nocturnal oxygenation, sleep architecture, PSQI, SGRQ-C, or SF 36 in both groups.

**Conclusion:** In patients with COPD inhaled triple therapy with budesonide-formoterol-tiotropium as compared to placebo-tiotropium improves pulmonary function while preserving sleep quality and architecture.
Introduction

Sleep quality is known to be poor in patients with chronic obstructive pulmonary disease (COPD). Subjectively, patients complain of insomnia, with reported difficulty initiating sleep, nocturnal awakenings, daytime sleepiness and impaired daytime concentration (1-6). Insomnia complaints appear to be more prevalent in those patients with associated daytime symptoms of cough, dyspnea, and wheezing (2,3). Objectively, poor sleep quality has been demonstrated, with an increased sleep latency, decreased total sleep time, increased arousal index, and decrease in N3 and rapid eye movement (REM) sleep (7-10). Disturbed sleep appears to be an important factor for the decrease in the quality of life (QOL) reported by these patients (6,11). In addition, disrupted sleep has been shown to be a predictor of COPD exacerbation rate and overall survival (12).

A number of factors have been suggested to be responsible for the poor sleep quality seen in patients with COPD. One is the development of nocturnal hypoxemia, which can occur despite the presence of an awake PaO2 > 60 mmHg (13,14). An association between nocturnal hypoxemia and objective assessment of sleep quality has been reported (1,10). Sympathetic activity, which is increased with chronic hypoxemia, may contribute to the disturbed sleep in these patients (15,16). While the effects of oxygen therapy on sleep quality have been variable (7,8,17,18) some studies have demonstrated improved sleep quality (7,18) which may be related to a decrease in sympathetic activity (19).
Poor sleep quality may also be related to the abnormal respiratory mechanics and increased work of breathing in COPD patients (10,20-22). Parameters of respiratory function and mechanics have been shown to predict sleep quality in these patients, as assessed quantitatively by polysomnography (10,22). Therapies that have been demonstrated to improve respiratory mechanics have been associated with an improvement in sleep quality (20,21). The improvement in sleep quality was seen despite the absence of an associated improvement in nocturnal oxygenation (21).

There are a number of medications used in the treatment of COPD that may affect sleep quality. Results have been variable, with some demonstrating either no effect or a worsening in sleep quality (23-31). In addition, there have been studies demonstrating an improvement in sleep quality, often associated with improvements in both nocturnal oxygenation and respiratory mechanics (6,32). Included were studies examining the effects of long-acting $\beta$-agonists and long-acting anticholinergics (6). More recently, triple therapy which includes an inhaled corticosteroid, long-acting $\beta$-agonist and long-acting anticholinergic has been shown to improve airway function, decrease exacerbations and improve QOL when compared to dual or single therapy in patients with COPD (33-42). However, the effect of triple therapy on sleep quality has not been previously studied in these patients. We hypothesized that triple therapy consisting of budesonide-formoterol-tiotropium would improve sleep quality as compared to placebo-tiotropium alone in patients with GOLD stage 2 and 3 COPD, possibly by improving nocturnal oxygenation and respiratory mechanics during sleep.
Methods

Patient Selection

Twenty-five consecutive patients with GOLD stage 2 and 3 COPD were recruited from the Pulmonary Clinic at Temple University Hospital to participate in the study. All of the patients were already on a bronchodilator regimen when they were asked to participate. Patients were excluded from the study if 1) they required supplemental oxygen, 2) they had a COPD exacerbation within the past 4 weeks, 3) they had a previous diagnosis of obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] > 10 events/hr), 4) they were taking an oral steroid medication, 5) there was a known history of urinary outflow obstruction, glaucoma, or a history of an allergic reaction to one of the study medications, and 6) in women of child-bearing age they had a positive pregnancy test. Patients were also excluded if they were not willing to participate in all aspects of the study, including an overnight polysomnogram, or were not willing to sign informed consent. The study was approved by the Lewis Katz School of Medicine at Temple University Institutional Review Board for Human Research (Philadelphia, PA).

Polysomnograms

Polysomnograms were performed while breathing room air following the American Academy of Sleep Medicine Guidelines (43). Sleep was staged and arousals defined using established criteria (33). Obstructive apneas were defined by the lack of airflow for greater than 10 seconds, associated with the presence of rib cage and abdominal movement (43). Obstructive hypopneas were defined
by a 30% decrease in airflow for greater than 10 seconds, associated with the presence of rib cage and abdominal movement, and
accompanied by an oxygen desaturation of $\geq 3\%$ or an arousal (43). Apneas were defined as central if there was a lack of respiratory
effort during the period of absent airflow (43). The AHI was calculated as the number of apneic and hypopnic events per hour of
sleep. Sleep efficiency was defined as the total sleep time / time in bed (%). All of the polysomnogram studies were initially scored
by a single senior technologist. The same author (SK) reviewed each study.

**Spirometry**

All spirometry was performed using the EasyOne spirometer (ndd Medical, Zurich, Switzerland) in accordance with American
Thoracic Society/European Respiratory Society recommendations (34). The largest FEV$_1$ and FVC from 3 acceptable maneuvers
were utilized even if they were from different forced expiratory curves (44).

**Questionnaires**

Subjective daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS) (45). The Pittsburgh sleep quality index
(PSQI) assesses sleep quality and disturbances over a 1-month time interval (46). The COPD-specific version of the St. George’s
Respiratory Questionnaire (SGRQ-C) was completed to assess disease specific impact to overall quality of life (47) and the short form
36 (SF 36) health survey questionnaire was completed to evaluate overall health status (48).
Protocol

Patients underwent an acquaintance night polysomnogram to account for a “first night” effect of sleeping in a new environment.

Patients were then asked to stop using any long-acting \(\beta\)-agonists or long-acting muscarinic antagonists and instructed to just use albuterol as needed until they returned after 2 weeks for a baseline polysomnogram study. Following the baseline polysomnogram study patients were randomized to one of two groups: 1) budesonide-formoterol 160 mcg/4.5 mcg – AM and PM + tiotropium 18 mcg - AM, or 2) placebo – AM and PM + tiotropium 18 mcg - AM. The investigators were blinded as to which group the patients were randomized. Randomization allocations were performed with a random number generator, using permuted blocks of 6. Patients then returned for a final polysomnogram study at the end of 28 days. Prior to the baseline and final polysomnogram studies patients completed the questionnaires and spirometry was performed prior to sleep onset in the sleep lab. During the 28 days of the study patients recorded their daily usage of albuterol required for rescue therapy.

Statistical Analysis

The data are presented as the median (interquartile range, range). Comparison of baseline data between the budesonide-formoterol-tiotropium and placebo-tiotropium groups was done using exact Wilcoxon rank-sums tests. Sign rank tests were used to evaluate the changes at 28 days post treatment in each of the groups. The Fisher Exact Test was performed to compare proportions between groups. No regression was conducted due to the small group sizes. The relationship between changes in spirometry values and sleep parameters were assessed by Spearman correlation coefficients. The sample size was estimated based on our previous study evaluating the effects
of noninvasive ventilation on sleep quality in COPD (21). In that study, we noted a 20% ± 5% SD increase in sleep efficiency with therapy. Using a similar increase in sleep efficiency, we calculated that we would need 10 patients in each group to achieve a 100% power to detect a similar change in sleep efficiency in those patients receiving budesonide-formoterol-tiotropium. Even using a more conservative change of 10% ± 10% would give a 90% power to detect this change with 10 patients in each group at an alpha of 0.05.

All statistical analyses were performed using a commercially available computer software program (SAS version 9.4, SAS Institute Inc., Cary, NC); p < 0.05 was considered statistically significant.

Results

Patient Characteristics

Twenty-three patients (11 (48%) males; age 55 (51-60, 48-75) yrs; body mass index [BMI] 25 (22-30, 18-40) kg/m²; FEV₁ 1.10 (0.80-1.90, 0.60-2.80) L, 42 (31-62, 24-75) % predicted) were enrolled and completed the study. Two patients were enrolled but did not complete the study; both had refused to undergo the final polysomnogram. Ten patients (6 (60%) males; age 59 (54-64, 50-70) yrs; BMI 25 (20-30, 18-32) kg/m²; FEV₁ 1.05 (0.8-1.10,0.70-2.80) L, 38 (30-65, 24-74) % predicted) were randomized to the budesonide-formoterol-tiotropium group and 13 patients (5 (39%) males; age 52 (51-56, 48-75) yrs; BMI 26 (22-30, 22-40) kg/m²; FEV₁ 1.20 (0.80-1.90, 0.60-2.40) L, 49 (35-58, 30-75) % predicted) were randomized to the placebo-tiotropium group, with no significant clinical difference between the 2 groups (Table 1).
Effects on Airflow Obstruction

At the end of 28 days there was a significant 29% increase in the bedtime FEV₁ in the budesonide-formoterol-tiotropium group (from 0.75 (0.55-1.30, 0.50-2.40) L to 1.00 (0.75-1.55, 0.50-3.00) L, p=0.031), with no significant change noted in the placebo-tiotropium group (from 1.20 (0.80-1.50, 0.60-1.90) L to 1.15 (0.75-1.55, 0.50-1.80) L, p=0.91) and a significant difference in the change in bedtime FEV₁ 28 days post treatment between the 2 groups (0.20 (0.10-0.45, -0.10-0.60) L vs. -0.05 (-0.20-0.10, -0.30-0.30) L, p=0.026) (Table 2). There was a similar significant increase in the bedtime FEV₁ % predicted in the budesonide-formoterol-tiotropium group (from 29 (23-37, 22-62) % pred to 38 (31-48, 25-79) % pred, p=0.039) with no significant change noted in the placebo-tiotropium group (from 46 (42-49, 27-60) % pred to 48 (38-57, 19-71) % pred, p=0.81), with a marginally significant difference in the change in bedtime FEV₁ % predicted 28 days post treatment between the 2 groups (7 (3-14, -3-26) % pred vs. -1 (-6-9, -12-15) % pred, p=0.086) (Table 2).

Effects on Sleep Quality

There was no significant change in sleep efficiency at the end of 28 days in the budesonide-formoterol-tiotropium group (from 78 (72-92, 62-98)% to 88 (77-92, 40-98)%, p=0.70) and in the placebo-tiotropium group (from 82 (75-88, 46-93)% to 84 (77-87, 62-94)%, p=0.96). In addition, the total sleep time did not change significantly at the end of 28 days in the budesonide-formoterol-tiotropium group (from 290 (268-358, 252-382) min to 342 (303-358, 157-372) min, p=0.77) and in the placebo-tiotropium group (from 320 (292-350, 180-378) min to 339 (303-349, 241-366) min, p=0.79). While there was no significant change in the arousal index in the
budesonide-formoterol-tiotropium group (from 9 (5-16, 0-48) arousals/hr to 14 (9-17, 2-36) arousals/hr, p=0.43), there was a significant increase seen in the placebo-tiotropium group (from 11 (4-13, 3-32) arousals/hr to 17 (11-21, 2-33) arousals/hr, p=0.027) (Table 2).

At the end of 28 days there was no significant change in the PSQI in the budesonide-formoterol-tiotropium group (from 7 (6-10, 4-15) to 6 (6-11, 4-15), p=0.53) and the placebo-tiotropium group (from 9 (9-11, 4-18) to 9 (9-11, 4-18), p=0.19). However, while there was no significant change in the ESS seen in the budesonide-formoterol-tiotropium group (from 6 (3-8, 0-11) to 6 (5-8, 0-11), p=0.44), there was a marginally significant increase in the placebo-tiotropium group (from 8 (5-12, 2-18) to 10 (7-13, 5-18), p=0.07), with a significant difference in the ESS between the 2 groups at the end of the 28 days (6 (5-8, 0-11) vs. 10 (7-13, 5-18), p=0.043). There was no significant change in sleep architecture noted at the end of 28 days in both the budesonide-formoterol-tiotropium group and placebo-tiotropium group (Table 2).

**Nocturnal Oxygenation and Sleep Disordered Breathing**

At the end of 28 days, there was no significant change in the budesonide-formoterol-tiotropium group and the placebo-tiotropium group in the mean oxygen saturation during the night (93 (91-95, 88-97)% to 93 (91-94, 88-97)%), p=0.50, and 95 (93-95, 91-97)% to 93 (91-94, 88-97)%), p=0.73, respectively), the lowest oxygen saturation during the night (88 (83-91, 74-92)% to 87 (81-89, 78-92)%, p=0.80, and 87 (84-90, 74-93)% to 87 (86-90, 84-97)% p=0.18, respectively), and the % total sleep time with an SaO₂ < 90% (1.4 (0-
18.2, 0.83.9)% to 0.95 (0.6-14.5, 0.77.7)% , p=0.30, and 1.3 (0.6.1, 0.21.1)% to 0.40 (0.5.7, 0.12.4)% , p=0.46, respectively). The AHI did not change in both the budesonide-formoterol-tiotropium group (1.3 (0.4-4.3, 0.7) events/hr to 0.9 (0.2-6.0, 0.8.2) events/hr, p=0.49) and the placebo-tiotropium group (0.8 (0.2-2.3, 0.5.2) events/hr to 0.5 (0.2.1, 0.15.9) events/hr, p=0.88) at the end of 28 days.

Quality of Life

There was no significant change at the end of 28 days in the budesonide-formoterol-tiotropium group and the placebo-tiotropium group for both the SGRQ-C (54 (42-60, 32-75) to 50 (42-51, 18-63), p=0.48, and 41 (27-61, 17-71) to 44±14, p=0.70, respectively) and the SF 36 for physical functioning (45 (33-68, 20-100) to 45 (33-61, 15-95), p=0.66, and 45 (30-68, 10-90) to 40 (30-65, 5-85), p=0.77, respectively) and the SF 36 for emotional well-being (76 (50-85, 40-96) to 86 (58-93, 28-96), p=0.21, and 68 (46-84, 32-92) to 60 (36-82, 20-100), p=0.19, respectively).

Discussion

Patients with COPD often report poor sleep quality, which can affect daytime function and overall quality of life (1-6,11). Disrupted sleep is noted even in those patients in whom associated OSA (OSA-COPD overlap syndrome) has been excluded (10,20). Many
factors have been suggested to be responsible for the poor sleep quality in these patients including nocturnal hypoxemia, abnormalities in respiratory mechanics, and the effects of prescribed medications (1,6,10,22-32). In regards to bronchodilator therapy, these studies have involved examining the effects of individual medications on sleep quality. In patients with severe underlying COPD, combinations of bronchodilators are more commonly used, with recent studies demonstrating improved lung function, reduced exacerbation rates and hospitalizations in those patients receiving triple therapy (inhaled corticosteroid, long-acting β-agonist, and long-acting anticholinergic) as opposed to single or dual therapy (33-42). However, no previous study has examined the effects of triple therapy on sleep quality.

There are 2 major findings in this study: 1) at the end of 28 days airflow obstruction significantly improved in the budesonide-formoterol-tiotropium group but not in the placebo-tiotropium group, and 2) the improvement in spirometry in the budesonide-formoterol-tiotropium group did not have a negative effect on quantitative and subjective measurements of sleep quality, nocturnal oxygenation, or subjective measurement of daytime function.

Poor sleep quality in patients with COPD is prevalent and associated with overall QOL (5,6,11,12). Budhiraja et al (6) reported insomnia to be present in 27.3% of COPD patients, with an associated lower QOL score as compared to those without insomnia. Nunes et al (11) found poor sleep quality, as determined by PSQI, to be the best predictor of QOL in 30 patients with GOLD stage 2-4 COPD. Omachi et al (12) demonstrated that disturbed sleep predicted both the incidence of COPD exacerbations and poorer survival.
Our patients had similar baseline characteristics both in regards to the severity of their obstructive disease as well as measurements of sleep quality and QOL.

In regards to the effects of bronchodilator medications on sleep quality in patients with COPD the results have been variable. Ryan et al (31) studied the effects of the long-acting β-agonist salmeterol on sleep quality and nocturnal oxygenation in 12 patients with COPD. Compared to placebo at the end of 4 weeks there was an increase in the mean SaO2 during the night but no change in sleep quality as assessed by polysomnogram. However, it should be noted that compared to placebo there was also no significant change in pulmonary function with salmeterol. Veale et al (26) also noted no significant change in sleep quality or nocturnal oxygenation after using the long-acting β-agonist salbutamol for 7 days as compared to placebo in 11 patients with COPD. Again, there was no significant change in spirometry when compared to placebo. More recently, Budhiraja et al (6) reported a lower prevalence of insomnia in those COPD patients that were using the β-agonists albuterol and formoterol.

In regards to the effects of inhaled anticholinergics on sleep quality in patients with COPD, Martin et al (32) examined the effects of 4 weeks of ipratropium bromide compared to placebo on sleep quality and pulmonary function in 36 patients with COPD. Compared to placebo, the ipratropium bromide group demonstrated an increase in pre-sleep forced vital capacity and flow rate at 50% of vital capacity. In regards to sleep quality, the ipratropium bromide group demonstrated an improvement in perceived sleep quality, an increase in REM time and mean SaO2 during the night but no change in total sleep time. McNicholas et al (28) studied the effects of 4 weeks of inhaled tiotropium on spirometry and sleep quality in 56 patients with COPD. While there was an improvement in
spirometry and SaO₂ during the night in the tiotropium group as compared to the placebo group, there was no change in sleep quality. The effects of theophylline on sleep quality and pulmonary function in COPD patients has also been examined, with the majority of studies demonstrating an improvement in spirometry and nocturnal oxygenation, but no change or a worsening in sleep quality (23-25,27,29). In the present study, there was a significant increase in spirometry in the budesonide-formoterol-tiotropium group but not in the placebo-tiotropium group at the end of 28 days. In regards to sleep quality, while there was no change in both objective and subjective sleep quality in the budesonide-formoterol-tiotropium group, there was a significant increase in the arousal index and ESS noted in the placebo-tiotropium group. However, the initial difference in the ESS scores in the budesonide-formoterol-tiotropium group and the placebo-tiotropium group (6 (3-8, 0-11) and 8 (5-12, 2-18), respectively) may lessen the clinical significance of the increase in the ESS noted in the placebo-tiotropium group. In addition, there were more female subjects in the placebo-tiotropium group (61%) than in the budesonide-formoterol-tiotropium group (40%) which may have an effect on our results. However, while female patients with COPD have been noted to have lower QOL scores than men (49), improvements in response to combination therapy as it relates to pre-treatment FEV₁, exacerbation rates and QOL appear to be similar between genders (50). Furthermore, in subjects without OSA, similar to our patients, women and men have been shown to have similar ESS scores (51).

Prior studies demonstrating an improvement in sleep quality with the use of nocturnal non-invasive ventilation or following lung volume reduction surgery in patients with COPD have suggested that a change in respiratory mechanics was responsible (20,21). In the present study, the significant increase in bedtime FEV₁ in the triple therapy group is probably related to a decrease in air trapping.
However, whether an associated improvement in respiratory mechanics contributed to the preserved sleep quality in the budesonide-formoterol-tiotropium group was not evaluated.

In regards to measurements of QOL, our study showed no change in QOL scores for both the budesonide-formoterol-tiotropium group as well as the placebo-tiotropium group as measured using the SF 36 and disease specific SGRQ-C scores. While prior studies using triple therapy have shown improvements in QOL scores, patients were treated over longer periods of time, anywhere from 12 weeks to as long as 1 year (33-42).

There are some limitations with the study that need to be addressed. First, the number of patients enrolled and who completed the study (23 patients) was small. However, it is similar to other studies which have evaluated the effects of inhaled bronchodilator medications on sleep quality and nocturnal oxygenation in patients with COPD (26,31,32). Second, the duration of the study at 28 day was relatively short. Although an improvement in spirometry was noted in the budesonide-formoterol-tiotropium group the effects on sleep quality and QOL may require a longer period of time on therapy. The time period is similar to other studies evaluating the effects of inhaled bronchodilator medications in these patients (28,31,32).

In conclusion, we demonstrated that compared to placebo-tiotropium, 28 days of the inhaled triple therapy of budesonide-formoterol-tiotropium improved pulmonary function and preserved sleep quality in patients with GOLD stage 2 and 3 COPD. Whether more prolonged use would lead to similar or more substantial effects on sleep quality awaits further investigation.
Acknowledgements

**Author Contributions:** SLK takes responsibility for the study as a whole. MEV, JD, HP, FJ, GED, WC, YMD, SC, XS, SW and GJC contributed to study design, data collection, data analysis, statistical analysis and manuscript preparation. TS contributed to polysomnogram data collection and scoring. DY contributed to the data analysis, statistical analysis and manuscript preparation.

**Declaration of Interests**

There was no conflict of interest in regards to the publication of this paper.
References


35) Short PM, Williamson PA, Elder DHJ, Lipworth SIW, Schembri S, Lipworth BJ. The Impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting B-agonist therapy in COPD. Chest 2102; 141(1):81-86.


<table>
<thead>
<tr>
<th>Variable</th>
<th>Budesonide- Formoterol-Tiotropium Group (n=10)</th>
<th>Placebo-Tiotropium Group (n=13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>59 (54-64, 50-70)</td>
<td>52 (51-56, 48-75)</td>
</tr>
<tr>
<td>Gender, Male/Female</td>
<td>6/4</td>
<td>5/8</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25 (20-30, 18-32)</td>
<td>26 (22-30, 22-40)</td>
</tr>
<tr>
<td>FEV₁, L</td>
<td>1.05 (0.8-1.10, 0.70-2.80) L</td>
<td>1.80 (1.50-2.90, 1.20-3.50)</td>
</tr>
<tr>
<td>FEV₁, % predicted</td>
<td>38 (30-65, 24-74)</td>
<td>49 (35-58, 30-75)</td>
</tr>
<tr>
<td>FVC, L</td>
<td>1.50 (4.70)</td>
<td>1.80 (1.50-2.90, 1.20-3.50)</td>
</tr>
<tr>
<td>FVC, % predicted</td>
<td>62 (52-88, 42-97)</td>
<td>62 (52-88, 42-97)</td>
</tr>
<tr>
<td>ESS</td>
<td>6 (3-8, 0-11)</td>
<td>8 (5-12, 2-18)</td>
</tr>
<tr>
<td>TST, min</td>
<td>290 (268-358, 252-382)</td>
<td>320 (292-350, 180-378)</td>
</tr>
<tr>
<td>Sleep Efficiency, %</td>
<td>78 (72-92, 62-98)</td>
<td>82 (75-88, 46-93)</td>
</tr>
<tr>
<td>Arousal index, events/hr</td>
<td>9 (5-16, 0-48)</td>
<td>11 (4-13, 3-32)</td>
</tr>
<tr>
<td>AHI, events/hr</td>
<td>1.3 (0.4-4.3, 0-7)</td>
<td>0.8 (0.2-2.3, 0-5.2)</td>
</tr>
<tr>
<td>Mean nocturnal SaO₂, %</td>
<td>93 (91-95, 88-97)</td>
<td>95 (93-95, 91-97)</td>
</tr>
<tr>
<td>Lowest nocturnal SaO₂, %</td>
<td>88 (83-91, 74-92)</td>
<td>87 (84-90, 74-93)</td>
</tr>
<tr>
<td>Sleep stage (%TST)</td>
<td>12 (7-17, 0-24)</td>
<td>9 (6-15, 3-25)</td>
</tr>
<tr>
<td>N1</td>
<td>59 (54-76, 52-81)</td>
<td>9 (6-15, 3-25)</td>
</tr>
<tr>
<td>N2</td>
<td>3 (0.2-8, 0-25)</td>
<td>55 (50-69, 42-78)</td>
</tr>
<tr>
<td>N3</td>
<td>17 (13-22, 7-34)</td>
<td>1 (0.1-16, 0-23)</td>
</tr>
<tr>
<td>REM</td>
<td>12 (7-17, 0-24)</td>
<td>21 (20-25, 10-30)</td>
</tr>
</tbody>
</table>

BMI: Body mass index; FEV₁: Forced expiratory volume in one second; FVC: Forced vital capacity; ESS: Epworth Sleepiness Scale; TST: Total sleep time; AHI: Apnea-hypopnea index; SaO₂: Oxygen saturation; REM: Rapid eye movement.
Table 2: Effect of Therapy in the 2 Treatment Groups after 28 Days

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline</th>
<th>28 Days</th>
<th>P Value</th>
<th>Baseline</th>
<th>28 Days</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁, L</td>
<td>0.75 (0.55-1.30, 0.50-2.40)</td>
<td>1.00 (0.75-1.55, 0.50-3.00)</td>
<td>0.031*</td>
<td>1.20 (0.80-1.50, 0.60-1.90)</td>
<td>1.15 (0.75-1.55, 0.50-1.80)</td>
<td>0.91</td>
</tr>
<tr>
<td>FEV₁, % predicted</td>
<td>29 (23-37, 22-62)</td>
<td>38 (31-48, 25-79)</td>
<td>0.039*</td>
<td>46 (42-49, 27-60)</td>
<td>48 (38-57, 19-71)</td>
<td>0.81</td>
</tr>
<tr>
<td>ESS</td>
<td>6 (3-8, 0-11)</td>
<td>6 (5-8, 0-11)</td>
<td>0.44</td>
<td>8 (5-12, 2-18)</td>
<td>10 (7-13, 5-18)</td>
<td>0.07</td>
</tr>
<tr>
<td>PSQI</td>
<td>7 (6-10, 4-15)</td>
<td>6 (6-11, 4-15)</td>
<td>0.53</td>
<td>9 (9-11, 4-18)</td>
<td>9 (9-11, 4-18)</td>
<td>0.19</td>
</tr>
<tr>
<td>TST, min</td>
<td>290 (268-358, 252-382)</td>
<td>342 (303-358, 157-372)</td>
<td>0.77</td>
<td>320 (292-350, 180-378)</td>
<td>339 (303-349, 241-366)</td>
<td>0.79</td>
</tr>
<tr>
<td>Sleep Efficiency, %</td>
<td>78 (72-92, 62-98)</td>
<td>88 (77-92, 40-98)</td>
<td>0.70</td>
<td>82 (75-88, 46-93)</td>
<td>84 (77-87, 62-94)</td>
<td>0.96</td>
</tr>
<tr>
<td>Arousal index, events/hr</td>
<td>9 (5-16, 0-48)</td>
<td>14 (9-17, 2-36)</td>
<td>0.43</td>
<td>11 (4-13, 3-32)</td>
<td>17 (11-21, 2-33)</td>
<td>0.027*</td>
</tr>
<tr>
<td>Mean nocturnal SaO₂, %</td>
<td>93 (91-95, 88-97)</td>
<td>93 (91-94, 88-97)</td>
<td>0.50</td>
<td>95 (93-95, 91-97)</td>
<td>93 (91-94, 88-97)</td>
<td>0.73</td>
</tr>
<tr>
<td>Lowest nocturnal SaO₂, %</td>
<td>88 (83-91, 74-92)</td>
<td>87 (81-89, 78-92)</td>
<td>0.80</td>
<td>87 (84-90, 74-93)</td>
<td>87 (86-90, 84-97)</td>
<td>0.18</td>
</tr>
<tr>
<td>Sleep stage (%TST)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>12 (7-17, 0-24)</td>
<td>8 (5-13, 4-30)</td>
<td>0.81</td>
<td>9 (6-15, 3-25)</td>
<td>9 (5-14, 2-22)</td>
<td>0.61</td>
</tr>
<tr>
<td>N2</td>
<td>59 (54-76, 52-81)</td>
<td>61 (47-74, 39-80)</td>
<td>0.57</td>
<td>55 (50-69, 42-78)</td>
<td>65 (55-70, 51-80)</td>
<td>0.19</td>
</tr>
<tr>
<td>N3</td>
<td>3 (0.2-8, 0-25)</td>
<td>2 (0-11, 0-32)</td>
<td>0.63</td>
<td>1 (0-16, 0-23)</td>
<td>2 (0-4, 0-26)</td>
<td>0.13</td>
</tr>
<tr>
<td>REM</td>
<td>17 (13-22, 7-34)</td>
<td>20 (15-23, 11-32)</td>
<td>0.26</td>
<td>21 (20-25, 10-30)</td>
<td>22 (15-26, 3-34)</td>
<td>0.78</td>
</tr>
</tbody>
</table>

FEV₁: Forced expiratory volume in one second; ESS: Epworth Sleepiness Scale; PSQI: Pittsburgh Sleep Quality Index; TST: Total sleep time; SaO₂: Oxygen saturation; REM: Rapid eye movement.

*p < 0.05